77% of patients experienced CRS, which was the most common adverse event with KYMRIAH. Although manageable, severe or life-threatening events have been observed.3
In almost all cases, development of CRS occurred between 1 and 10 days after KYMRIAH infusion (median onset, 3 days), with a median time to resolution of 8 days.
Hypogammaglobulinaemia and agammaglobulinaemia can occur in patients after KYMRIAH infusion.
The majority of neurological events occurred within 8 weeks following KYMRIAH infusion and were transient.
aInfections and infestations presented reflect high level group terms.
bHaemorrhage includes anal haemorrhage, blood urine present, catheter site haemorrhage, cerebral haemorrhage, conjunctival haemorrhage, contusion, cystitis haemorrhagic, duodenal ulcer haemorrhage, disseminated intravascular coagulation, epistaxis, eye contusion, gastrointestinal haemorrhage, gingival bleeding, haematochezia, haemarthrosis, haematemesis, haematuria, haemoptysis, large intestinal haemorrhage, melaena, menorrhagia, mouth haemorrhage, peritoneal haematoma, petechiae, pharyngeal haemorrhage, post procedural haemorrhage, pulmonary haemorrhage, purpura, retinal haemorrhage, traumatic haematoma, tumour haemorrhage, upper gastrointestinal haemorrhage and vaginal haemorrhage.
cHypogammaglobulinaemia includes immunoglobulins decreased, blood immunoglobulin A decreased, blood immunoglobulin G decreased, blood immunoglobulin M decreased, immunodeficiency, immunodeficiency common variable and hypogammaglobulinaemia.
dDelirium includes agitation, delirium, hallucination, hallucination visual, irritability and restlessness.
eSleep disorder includes sleep disorder, insomnia and nightmare.
fHeadache includes headache and migraine.
gEncephalopathy includes depressed level of consciousness, mental status changes, automatism, cognitive disorder, confusional state, disturbance in attention, encephalopathy, somnolence, lethargy, memory impairment, metabolic encephalopathy and thinking abnormal.
hDizziness includes dizziness, presyncope and syncope.
iPeripheral neuropathy includes paraesthesia, peripheral sensory neuropathy, neuropathy peripheral, hyperaesthesia and hypoaesthesia.
jTremor includes dyskinesia and tremor.
kMotor dysfunction includes muscle spasms, muscle twitching, myoclonus and myopathy.
lSeizure includes seizure, generalised tonic clonic seizures and status epilepticus.
mSpeech disorders includes speech disorders, dysarthria and aphasia.
nNeuralgia includes neuralgia and sciatica.
oAtaxia includes ataxia and dysmetria.
pVisual impairment includes vision blurred and visual impairment.
qArrhythmia includes atrial fibrillation, supraventricular tachycardia, tachycardia and ventricular extrasystoles.
rCardiac failure includes cardiac failure, left ventricular dysfunction, cardiac failure congestive and right ventricular dysfunction.
sHypotension includes hypotension and orthostatic hypotension.
tThrombosis includes deep vein thrombosis, embolism, pulmonary embolism, thrombosis, vena cava thrombosis and venous thrombosis.
uCough includes cough, productive cough and upper airway cough syndrome.
vDyspnoea includes dyspnoea, dyspnoea exertional, respiratory distress and respiratory failure.
wOropharyngeal pain includes oral pain and oropharyngeal pain.
xPulmonary oedema includes acute pulmonary oedema and pulmonary oedema.
yAbdominal pain includes abdominal pain, abdominal pain upper and abdominal discomfort.
zRash includes dermatitis, dermatitis acneiform, dermatitis contact, rash, rash maculopapular, rash papular and rash pruritic.
aaAcute kidney injury includes acute kidney injury, anuria, azotaemia, blood creatinine abnormal, blood creatinine increased, renal failure, renal tubular dysfunction and renal tubular necrosis.
bbFatigue includes fatigue and malaise.
ccOedema includes oedema peripheral, generalised oedema, localised oedema, face oedema and peripheral swelling.
ddPain includes pain and pain in extremity.
*Frequency is based on laboratory values. Patients are counted only for the worst grade observed post baseline.
You are now leaving KYMRIAH.com and moving to a site that is for qualified treatment centres only. A log-in and password will be required to access information on this site.
Coming soon
A list of qualified treatment centres near you
You are now leaving KYMRIAH.com and moving to a site that is for qualified treatment centres only. A log-in and password will be required to access information on this site.
You are now leaving KYMRIAH.com and will be redirected to Novartis.com to review the press release.